Futibatinib, soluble in DMSO and insoluble in ethanol and water, is a protein tyrosine kinase inhibitor that has shown potent biochemical activity against FGFR. It targets FGFR1, FGFR2, FGFR2 E566G, FGFR2 N550H, FGFR2 V5651, FGFR3, FGFR4, and wild-type FGFR2.
Futibatinib is employed in exploring FGFR as a selective inhibitor, aiding in the development of FGFR-targeted cancer therapies.
Publications
Publications (0)
×
Publications
Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.
As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.
*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.